222 related articles for article (PubMed ID: 33260050)
1. Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Rajan A; Nadhan R; Latha NR; Krishnan N; Warrier AV; Srinivas P
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188482. PubMed ID: 33260050
[TBL] [Abstract][Full Text] [Related]
2. Modulation of BRCA1 mediated DNA damage repair by deregulated ER-α signaling in breast cancers.
Rajan A; Varghese GR; Yadev I; Anandan J; Latha NR; Patra D; Krishnan N; Kuppusamy K; Warrier AV; Bhushan S; Nadhan R; Ram Kumar RM; Srinivas P
Am J Cancer Res; 2022; 12(1):17-47. PubMed ID: 35141003
[TBL] [Abstract][Full Text] [Related]
3.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
4. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Suba Z
Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
7. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
8. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
9. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
10. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H; Li H; Chun P; Avraham S; Avraham HK
Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
[TBL] [Abstract][Full Text] [Related]
11. [BRCA1 and Estrogen Receptor α Expression Regulation in Breast Cancer Cells].
Scherbakov AM; Shestakova EA; Galeeva KE; Bogush TA
Mol Biol (Mosk); 2019; 53(3):502-512. PubMed ID: 31184616
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability.
Savage KI; Matchett KB; Barros EM; Cooper KM; Irwin GW; Gorski JJ; Orr KS; Vohhodina J; Kavanagh JN; Madden AF; Powell A; Manti L; McDade SS; Park BH; Prise KM; McIntosh SA; Salto-Tellez M; Richard DJ; Elliott CT; Harkin DP
Cancer Res; 2014 May; 74(10):2773-2784. PubMed ID: 24638981
[TBL] [Abstract][Full Text] [Related]
13. Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen NA; Schwartz GN; Tau S; Roberts AM; Jiang A; Hosford SR; Marotti JD; Goen AE; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
Clin Cancer Res; 2023 Sep; 29(18):3717-3728. PubMed ID: 37439680
[TBL] [Abstract][Full Text] [Related]
14. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
15. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
Roldán G; Delgado L; Musé IM
Cancer Biol Ther; 2006 May; 5(5):505-10. PubMed ID: 16582598
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 regulates human mammary stem/progenitor cell fate.
Liu S; Ginestier C; Charafe-Jauffret E; Foco H; Kleer CG; Merajver SD; Dontu G; Wicha MS
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1680-5. PubMed ID: 18230721
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
Wang L; Di LJ
Int J Biol Sci; 2014; 10(5):566-75. PubMed ID: 24910535
[TBL] [Abstract][Full Text] [Related]
18. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence.
Graziano S; Johnston R; Deng O; Zhang J; Gonzalo S
Oncogene; 2016 Oct; 35(41):5362-5376. PubMed ID: 27041576
[TBL] [Abstract][Full Text] [Related]
20. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity.
Ma Y; Hu C; Riegel AT; Fan S; Rosen EM
Mol Endocrinol; 2007 Aug; 21(8):1905-23. PubMed ID: 17505062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
